Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160393 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL4386268 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL9165455 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL837479 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL4650965 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL427955 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL868174 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL3149218 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL1703685 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL5302396 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970793-B | Process method for synthesizing carbon pentadecatriphenyl phosphine salt | 广州智特奇生物科技股份有限公司 | 2021-03-12 | — | — | CN | claimed |
| CN-113201016-A | Preparation method of C15 phosphonium salt | 万华化学集团股份有限公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-109970793-B | Process method for synthesizing carbon pentadecatriphenyl phosphine salt | 广州智特奇生物科技股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-109970793-B | Process method for synthesizing carbon pentadecatriphenyl phosphine salt | 广州智特奇生物科技股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2827899-B1 | POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2827899-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-28 | — | — | EP | disclosed |
| CN-104321079-A | Carbohydrate-glycolipid conjugate vaccines | MAX PLANCK GESELLSCHAFT | 2015-01-28 | — | — | CN | disclosed |
| WO-2013178236-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013139803-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-09-26 | — | — | WO | disclosed |
| US-7923013-B2 | Glycolipids and analogues thereof as antigens for NKT cells | THE ROCKEFELLER UNIVERSITY (US) | 2011-04-12 | — | — | US | disclosed |
| US-7534434-B2 | Glycolipids and analogues thereof as antigens for NK T cells | THE ROCKEFELLER UNIVERSITY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | THE ROCKEFELLER UNIVERSITY (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006131234-A1 | COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
| EP-0045100-B1 | PROCESS FOR THE TRANSFORMATION OF AN ALDEHYDE INTO ALKENE, IN PARTICULAR OF FURFURAL INTO FURFURYLIDENES | AGRIFURANE S.A. (FR) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | MEN1 2616/4885KMT2A 2780/4885DNM1 4469/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | MEN1 2616/4885KMT2A 2780/4885DNM1 4469/4885 |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | CD69, KLRK1, PBK | MEN1 4145/4885KMT2A 1889/4885DNM1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.